Replies to post #642074 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I have not seen anything released by NWBio recently. But, I believe the Specials Program in the UK includes all malignant brain tumors, including nGBM and rGBM, and all Grade 3 malignant brain tumors.

Also, when NWBio received the EAMS and PIM designation from the MHRA back in 2014, it included all malignant brain tumors:

The PIM designation for DCVax-L covers all malignant gliomas, which would include both Glioblastoma multiforme (the most severe grade) as well as less malignant grades, and would include both newly diagnosed and recurrent gliomas.

https://nwbio.com/nw-bios-cancer-vaccine-is-the-first-drug-to-be-designated-by-uk-authorities-as-a-promising-innovative-medicine-pim/

I believe the key, is whether or not the brain tumor is considered to be malignant. That would apply to all Grade 4 brain tumors, and some Grade 3 brain tumors.